Research Article

Efficacy of Trastuzumab + Cisplatin Combined with Irinotecan on the Quality of Life of Patients with Advanced Her-2 Positive Gastric Cancer

Table 1

Comparison of general information of the two groups of patients (n = 60).

Control groupJoint groupX2/t

Age (years)59.86 ± 4.7260.14 ± 5.030.3140.754
Male/female41/1938/220.3330.564
TNM staging

IIIa15 (25)14 (23.33)0.0460.831
IIIb21 (35)20 (33.33)0.0370.847
IV24 (40)26 (43.33)0.1370.711
Disease site

Fundus of stomach26 (43.33)25 (41.67)0.0340.853
Gastric antrum23 (38.33)25 (41.67)0.1390.709
Cardia11 (18.33)10 (16.67)0.0580.810
Tumor typing

Poorly differentiated diffuse carcinoma27 (45)25 (41.67)0.1360.713
Moderately differentiated adenocarcinoma15 (25)16 (26.67)0.0440.835
Poorly differentiated adenocarcinoma13 (21.67)12 (20)0.0510.822
Hepatoid adenocarcinoma3 (5)4 (6.67)0.1520.697
Mucinous adenocarcinoma2 (3.33)3 (5)0.2090.648